Hawk Kim
Korean Society of Hematology · Ulsan University Hospital · Ulsan University Hospital, University of Ulsan College of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hawk Kim as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 02:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06368414 · A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid LeukemiaKorean Society of Hematology · recruiting · Chronic Myeloid Leukemia, Chronic Phase · study chair
- Ph2NCT02422719 · Radotinib as 3rd or Later Line Therapy in CP-CMLUlsan University Hospital · unknown · Chronic Myeloid Leukemia · principal investigator
- Ph2NCT01690065 · Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AMLUlsan University Hospital · unknown · Chronic Myeloid Leukemia in Myeloid Blast Crisis, Untreated Adult Acute Myeloid Leukemia · principal investigator
- Ph2NCT01673308 · Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic SyndromeUlsan University Hospital · unknown · Myelodysplastic Syndrome · principal investigator
- Ph3NCT01145976 · Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic AnemiaCooperative Study Group A for Hematology · unknown · Aplastic Anemia · principal investigator
- Ph2NCT00561301 · Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant LymphomaCooperative Study Group A for Hematology · unknown · Lymphoma · principal investigator
- Ph2NCT00559221 · FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AMLCooperative Study Group A for Hematology · unknown · Acute Myeloid Leukemia · principal investigator
- Ph2NCT00529880 · Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AMLCooperative Study Group A for Hematology · unknown · Acute Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 02:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in chronic myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 02:00 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.Clin Cancer Res · 2003264 citationsRCR 5.0
- Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.J Clin Oncol · 2009147 citationsRCR 3.3
- Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.Clin Cancer Res · 201765 citationsRCR 1.9
- Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.Haematologica · 201461 citationsRCR 1.7
- 29 citationsRCR 0.9
- Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).Br J Haematol · 202020 citationsRCR 0.9
- Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.Ann Hematol · 201014 citationsRCR 0.3
- A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.Cancer Med · 201810 citationsRCR 0.5
- Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.Bone Marrow Transplant · 20048 citationsRCR 0.2
- Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.Biol Blood Marrow Transplant · 20046 citationsRCR 0.1